Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. META
4. ABBV
5. FDX
6. IBM
7. MU
8. PFE
9. AWK
10. ACN

Go back to Biogen Announces AFFINITY Phase 2 Trial Initiation for Opicinumab (Anti-LINGO-1) in Multiple Sclerosis

Biogen (BIIB) PT Raised to $355 at Leerink Partners

October 25, 2017 7:29 AM EDT

Leerink Partners raised its price target on Biogen (NASDAQ: BIIB) to $355.00 (from $351.00) while maintaining a Market Perform rating.

... More